Achille Désiré Betené Omgba^1,2,*, Cheryle Manfouo Tchoupmene¹, Benoit Ndiwe^1,2,*, Antonios N. Papadopoulos³, Remy Legrand Ndoumou Belinga¹, Julien Clerc Obam¹, Christel Cedrig Laris Nsi Ongo¹, Ioanna A. Papadopoulou⁴, Armel Brice Mvogo^1,2, Fabien Betené Ebanda^1,2, Atangana Ateba^1,2, Antonio Pizzi⁵

Journal of Renewable Materials, Vol.14, No.3, 2026, DOI:10.32604/jrm.2026.02025-0201 - 25 March 2026

Abstract The high hydrophilicity of pineapple leaf fibres (PALF) limits their use in cement- and gypsum-based composites exposed to moisture. This study evaluates, for the first time, the combined effect of palm kernel oil and beeswax on the hygroscopic resistance and mechanical stability of PALF. The fibres were functionalised with three formulations (oil, wax, and a 1:2 oil/wax blend) applied at different mass ratios (CR = 0.5–2). Treatments increased the average bundle diameter by up to +46% (238 μm) and reduced density down to 1.06 g/cm³. Hygroscopically, water absorption decreased from 202.4% (raw fibres) to 76.3% (CR… More > Graphic Abstract

H. A. Aisyah^1,*, I. Nur Azreena², E. Hishamuddin¹, A.W. Noorshamsiana¹, N. M. Nurazzi²

Journal of Renewable Materials, Vol.14, No.3, 2026, DOI:10.32604/jrm.2025.02025-0141 - 25 March 2026

Abstract Oil palm fiber is a natural fiber derived from agricultural biomass and has gained significant attention as an alternative reinforcement material in composite materials due to its abundance, renewability, and environmental benefits. This review explores the various enhancement techniques applied to oil palm fiber to improve its properties for composite material development. Key areas of focus include chemical treatments, physical modifications, and hybridization with other fibers to improve fiber-matrix bonding, mechanical strength, and thermal stability. Integration of nanomaterials and bio-based resins to enhance the performance and sustainability of oil palm fiber composites is also discussed. More > Graphic Abstract

Eshita Dhar^1,2, Muhammad Ashad Kabir³, Divyabharathy Ramesh Nadar⁴, Li-Jen Kuo⁵, Jitendra Jonnagaddala^6,7, Yaoru Huang¹, Mohy Uddin^8,*, Shabbir Syed-Abdul^1,2,9,*

Oncology Research, Vol.34, No.4, 2026, DOI:10.32604/or.2026.074385 - 23 March 2026

Abstract Objectives: Decisions regarding CT after nCCRT for locally advanced rectal cancer (LARC) are challenging due to limited evidence guiding treatment. This study aimed to (i) evaluate the predictive performance of machine learning (ML) models in patients treated with neoadjuvant concurrent chemoradiotherapy (nCCRT) alone vs. those receiving nCCRT plus chemotherapy (CT), (ii) identify features associated with treatment improvement, and (iii) derive ML-based thresholds for treatment response. Methods: This retrospective study included 409 patients with LARC treated at three affiliated hospitals of Taipei Medical University. Patients were categorised into two groups: nCCRT alone followed by surgery (n =… More >

Vincenzo Montanarella¹, Marcelo Guerrero^2,3, David Filho^2,3, Júlia German-Cortés¹, Giacomoluciano Vitelli¹, Magalí Sureda¹, Carlos Pavón Regaña¹, Roser Ferrer^1,4, Simó Schwartz^1,4, Esteban Durán-Lara^2,3, Fernanda Andrade^1,5,*, Diana Rafael^1,6,*

Oncology Research, Vol.34, No.4, 2026, DOI:10.32604/or.2026.074061 - 23 March 2026

Abstract Despite remarkable advances in nanomedicine, localized delivery of advanced cancer therapeutics remains underexploited. Advanced therapies based on biopharmaceuticals, immunotherapy, or gene therapy have revolutionized oncology. Yet, their systemic administration is often associated with limitations such as poor site-specific accumulation, instability, and systemic toxicity. Hydrogels/macrogels offer the ability to encapsulate, protect, and release biomolecules in situ with sustained and stimulus-responsive profiles, addressing key translational gaps. This review provides a focused synthesis of the last five years of hydrogel-based research for cancer therapy, with emphasis on peptides, antibodies, immunotherapeutic agents, and gene delivery systems. We discuss design principles,… More > Graphic Abstract

Mohsina Patwekar^1,2, Faheem Patwekar³, Zulhisyam Abdul Kari^1,4,*, Muhammad Rajaei Ahmad Mohd Zain^5,*, Arifullah Mohammed⁶, Rohit Sharma^7,*

Oncology Research, Vol.34, No.4, 2026, DOI:10.32604/or.2026.073601 - 23 March 2026

Abstract Breast cancer remains the primary cause of cancer-related mortality for women globally; therefore, further breakthroughs in treatment approaches are crucial. Palbociclib, ribociclib, and abemaciclib are among the Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors that have become an innovative family of targeted therapy for hormone receptor-positive, Human Epidermal Growth factor receptor 2 (HR+/HER2−) breast cancer. These inhibitors work by preventing the action of CDK4/6, which are crucial in the regulation of the cell cycle. Leading cancer cells to cell cycle arrest and undergo apoptosis. When these inhibitors are used with endocrine medicines like letrozole and… More > Graphic Abstract

Francesco Chiari^1,*, Giovanni Motta², Daria Maria Filippini³, Claudio Donadio Caporale¹, Pierre Guarino¹

Oncology Research, Vol.34, No.4, 2026, DOI:10.32604/or.2026.073086 - 23 March 2026

Abstract Objective: Mucoepidermoid carcinoma (MEC) of the larynx is an extremely rare malignancy, accounting for less than 1% of primary laryngeal tumors. The optimal role of adjuvant therapy, particularly radiotherapy (RT), remains unclear due to limited evidence. This systematic review aimed to evaluate oncologic outcomes and the impact of adjuvant treatment in patients with early- and advanced-stage laryngeal MEC. Methods: A systematic literature search was performed according to PRISMA 2020 guidelines in PubMed/Embase, Scopus, and Cochrane for studies published up to 31 July 2025. Results: Twenty-two studies, encompassing 55 patients, were included. Early-stage (T1–T2) patients (n =… More >

Andrea Dalbeni^1,2, Marco Vicardi^1,2,*, Leonardo A. Natola^1,2, Alessandra Auriemma³, Bernardo Stefanini⁴, Caterina Vivaldi⁵, Piera Federico⁶, Andrea Polloni⁷, Caterina Soldà⁸, Lorenzo Lani⁴, Ingrid Garajová⁹, Stefano Tamberi¹⁰, Stefania De Lorenzo¹¹, Fabio Piscaglia^4,12, Vincenzo Di Maria¹, Gianluca Masi⁵, Sara Lonardi⁸, Giovanni Brandi^4,7, Bruno Daniele⁶, Franco Trevisani^4,13, Gianluca Svegliati-Baroni¹⁴, Laura Schiada¹⁴, Fabio Marra¹⁵, Claudia Campani¹⁵, Ciro Celsa¹⁶, Giuseppe Cabibbo¹⁶, Mariangela Bruccoleri¹⁷, Massimo Iavarone^17,18, Leonardo Stella¹⁹, Francesca R. Ponziani¹⁹, Tiziana Pressiani²⁰, Lorenza Rimassa^20,21, Francesco Tovoli⁴, David Sacerdoti²

Oncology Research, Vol.34, No.4, 2026, DOI:10.32604/or.2026.073063 - 23 March 2026

Abstract Objectives: The combination of atezolizumab plus bevacizumab (A+B) represents one of the standards first-line treatments for unresectable hepatocellular carcinoma (HCC). Metformin has garnered attention for its potential antitumour and immunomodulatory properties beyond glycaemic control. This study aimed to assess metformin’s impact in patients with type 2 diabetes mellitus (T2DM) receiving A+B therapy. Methods: This retrospective analysis of a prospectively-maintained multicentre database included 523 patients with HCC treated with A+B from the ARTE (Atezolizumab-bevacizumab Real-life Experience for Treatment of Hepatocellular Carcinoma) dataset across 18 Italian centres (May 2020–January 2024). We evaluated objective response rate (ORR), disease… More >

Paolo Maione^1,*, Valentina Palma^1,2, Cesare Gridelli¹

Oncology Research, Vol.34, No.4, 2026, DOI:10.32604/or.2026.072992 - 23 March 2026

Abstract After about 20 years of exciting improvements in treatment efficacy outcomes of advanced epidermal growth factor receptor (EGFR) mutant and anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer (NSCLC), also combined with a progressively better safety profile, from chemotherapy to new generation tyrosine kinase inhibitors (TKIs) (osimertinib, alectinib, brigatinib), the recent MARIPOSA and CROWN trials have changed this trend. For the first time in the history of EGFR and ALK treatments, we must face the issue of being a step behind in terms of toxicity profile. The combination of amivantamab plus lazertinib in EGFR mutant NSCLC, and… More >

Yin-Lun Chang^1,2, Hao-Lun Luo¹, Jei-Ming Peng^3,*, Chang-Chun Hsiao^2,*

Oncology Research, Vol.34, No.4, 2026, DOI:10.32604/or.2026.070837 - 23 March 2026

Abstract Background: Upper tract urothelial carcinoma (UTUC) is an aggressive malignancy with high recurrence rates. Lymphovascular invasion (LVI) predicts a poor prognosis, yet its molecular drivers remain unclear. BOC cell adhesion-associated, oncogene-regulated (BOC, also known as Brother of CDO [Cell adhesion molecule-Related/Down-regulated by Oncogenes]), a hedgehog-related cell surface receptor, may serve as a biomarker for tumor progression and chemotherapy response. The study aimed to investigate the role of BOC in UTUC and its potential to predict LVI and chemotherapy response. Methods: Sequencing (RNA-seq) of 10 stage III UTUC, treatment-naïve, fresh tissue samples identified BOC as a… More >

Yingying Zhao^1,2, Jiakang Ma^1,3, Rujin Huang^1,2, Shuxian Pan^1,*

Oncology Research, Vol.34, No.4, 2026, DOI:10.32604/or.2026.070208 - 23 March 2026

Abstract Background: Cancer-associated fibroblasts (CAFs) play critical roles in tumor progression and immunosuppression; however, their contribution to the functional classification and personalized treatment of gastric cancer remains poorly defined. This study aimed to identify effective therapeutic targets to facilitate individualized treatment strategies for patients with gastric cancer. Methods: Single-cell and bulk transcriptomic analyses were integrated to characterize gastric cancer fibroblasts. “Seurat”, “Slingshot”, and “CellChat” were used for dimensionality reduction, trajectory inference, and cell–cell communication analyses, respectively. Key metastasis-associated fibroblast modules were identified using High-dimensional weighted gene co-expression network analysis (hdWGCNA) to construct a prognostic model, which was further… More > Graphic Abstract